Compare Enbridge Inc (ENB) vs Immunovant Inc. Common Stock (IMVT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Immunovant Inc. Common Stock — how do they compare? Enbridge Inc trades at $46.45 (market cap $103.38B), while Immunovant Inc. Common Stock trades at $30.25 (market cap $6.25B). The key difference: Enbridge Inc is far larger — about 16.5× Immunovant Inc. Common Stock's market cap, and Enbridge Inc pays a 6.02% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Enbridge Inc for 91 Days and Immunovant Inc. Common Stock for 0 Days on average.
| ENB | IMVT | |
|---|---|---|
Market Cap | $103.38B | $6.25B |
Volume | 3,684,305 | 1,755,411 |
Sector | Energy | Health |
52-Week High | $58.04 | $44.96 |
52-Week Low | $45.23 | $17.03 |
Typical Hold Time | 91 Days | 0 Days |
Enterprise Value | $185.39B | $5.35B |
Dividend Yield | 6.02% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $45.89, down 1.4% with bearish technical signals despite strong fundamentals. The company reported Q2 2026 EPS of $0.46, beating expectations by 7%, and maintains a 6% dividend yield. Revenue grew to $65.19B in 2025 with net income of $7.49B, though 2026 projections show margin compression. Analyst consensus is mixed with 48% buy ratings and a $61.63 price target suggesting 34% upside potential.
ENB presents a value opportunity with discounted valuation metrics (P/E 25.27, P/S 1.72) and stable cash flows, but faces headwinds from rising interest rates and energy market volatility. The stock's current technical weakness contrasts with fundamental strength, creating potential for recovery if operational execution continues to outperform expectations.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →
